{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-028093","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.510564+00:00","generated_at":"2026-05-17T08:51:30.016825+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pulse Biosciences enrolls first patients in PRECISE-BTN study for benign thyroid nodules","bullets":["First successful procedures using nsPFA Percutaneous Electrode System for benign thyroid nodules (BTNs).","Multicenter IRB-approved study will enroll up to 50 patients across four sites.","Endpoints include safety, nodule volume reduction, symptom relief, quality of life, and cosmesis at 1, 3, 6, 12 months.","CEO notes ongoing commercial launch pilot phase alongside clinical study progression.","Principal investigator reports early positive results and organ-sparing potential."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-028093","json":"https://secwatch.observer/filing/0001437749-25-028093.json","markdown":"https://secwatch.observer/filing/0001437749-25-028093.md","text":"https://secwatch.observer/filing/0001437749-25-028093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925028093/0001437749-25-028093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925028093/plse20250829_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:51:30.016825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}